Lannett Co Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LANNETT CO INC, and what generic and branded alternatives to LANNETT CO INC drugs are available?
LANNETT CO INC has one hundred and thirty-five approved drugs.
Summary for Lannett Co Inc
US Patents: | 0 |
Tradenames: | 102 |
Ingredients: | 96 |
NDAs: | 135 |
Drug Master File Entries: | 1 |
Drugs and US Patents for Lannett Co Inc
Expired US Patents for Lannett Co Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-002 | Jun 19, 2003 | 6,344,215 | See Plans and Pricing |
Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-003 | May 27, 2003 | 6,344,215 | See Plans and Pricing |
Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-004 | Feb 19, 2006 | 6,344,215 | See Plans and Pricing |
Lannett Co Inc | METADATE CD | methylphenidate hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 021259-001 | Apr 3, 2001 | 6,344,215 | See Plans and Pricing |
Lannett Co Inc | MYKROX | metolazone | TABLET;ORAL | 019532-001 | Oct 30, 1987 | 4,517,179 | See Plans and Pricing |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LANNETT CO INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
➤ Subscribe | Extended-release Capsules | 40 mg | ➤ Subscribe | 2007-03-15 |
➤ Subscribe | Extended-release Capsules | 10 mg, 20 mg and 30 mg | ➤ Subscribe | 2005-05-13 |
Similar Applicant Names
Here is a list of applicants with similar names.